The Latest
-
Courtesy of GSK Flickr page
How pharma CEO pay shifted for these 4 companies last year
Top executives saw big pay changes in a year defined by slower M&A and political uncertainty.
-
Permission granted by ixlayer
Sponsored by ixlayerTransforming biopharma’s approach to patient engagement with direct-to-patient programs
Consumers want more from biopharma. Next-generation direct-to-patient programs can deliver.
-
Permission granted by Teva
Teva targets schizophrenia to build on innovative medicines growth
The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.
-
Permission granted by Recursion
Q&AAI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration
Recursion CFO Ben Taylor discusses the state of AI M&A and what companies should look for as the industry moves to new data technologies and systems.
-
Stock via Getty Images
Its CEO died. The company scrapped a promising program. Now, for their 2nd act.
Terns Pharmaceuticals sees blockbuster promise for two potential best-in-class molecules in obesity and oncology.
-
Getty Images via Getty Images
Cancer vaccines have stumbled, but the approach is gaining new steam
The number of candidates in development has nearly doubled over the past 15 years.
-
George Clerk via Getty Images
Pfizer names Patrizia Cavazzoni, former top FDA official, as chief medical officer
Cavazzoni stepped down from her role as head of the FDA’s main drug review office in mid-January. She will succeed Aida Habtezion.
-
Getty Images via Getty Images
Incentivizing rare disease R&D is getting tougher, but revamped policies could turn the tide
Orphan drug development has long been incentivized by government policy. But as the financial math shifts, so do the risks of bringing rare disease drugs to market.
-
Chip Somodevilla via Getty Images
Kennedy’s MAHA agenda is tackling ‘conflicts of interest’ — and could take aim at FDA adcomms
Health agency job cuts and a newly-established MAHA commission leave many unanswered questions about potential reforms and impact on drug approvals.
-
Stock via Getty Images
A look at Trump’s healthcare cuts — so far
How the federal workforce crackdown has impacted the agencies that oversee pharma and healthcare.
-
Sarah Silbiger via Getty Images
In FDA job cuts, experts see threat of far-reaching impact
"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency commissioner Robert Califf, of the layoffs.
-
Permission granted by Immunocore
Q&A // First 90 DaysLilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO
Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.
-
Stock via Getty Images
Q&AMerck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production
The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.
-
Drew Angerer via Getty Images
Challenges mount for vaccine makers
End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.
-
Stock via Getty Images
Biotech SpotlightCRISPR’s cardio catch-all drives a biotech’s broad potential
Scribe Therapeutics hopes to prevent cardiometabolic diseases by targeting underlying causes with CRISPR technology.
-
Stock via Getty Images
Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split
The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.
-
Stock via Getty Images
Are orexins the next golden child of neuroscience?
An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.
-
Spencer Platt via Getty Images
Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma
The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive overhaul or incremental change.
-
Stock via Getty Images
In the crowded cardio space, it’s David vs. Goliath for small biotechs
What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.
-
Stock via Getty Images
The kids are alright: How pharma can make inroads with Gen Z
As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.
-
Permission granted by Fractyl Health
Q&A // Biotech SpotlightBeyond GLP-1s? This biotech is exploring longer-term metabolic treatments
Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.
-
Anatolii Kovalov via Getty Images
Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions
While the 10% tariff on Chinese goods won’t have too much impact on branded drugs, generics are struggling to pivot.
-
Permission granted by Bristol Myers Squibb
Bristol Myers gives first peek at closely watched launch of schizophrenia drug
Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.
-
cagkansayin via Getty Images
With uncertainty roiling Big Pharma, execs are placing lower-risk bets
The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.
-
Stock via Getty Images
As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D
With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.
-
Win McNamee via Getty Images
RFK Jr. will face these critical tests if confirmed as head of the HHS
After a Senate committee advanced President Trump’s nominee to lead HHS, Robert F. Kennedy Jr. is poised to secure the top job at the nation’s healthcare agency.
